Cantor Fitzgerald Keeps a Sell Rating on Bluebird Bio

By Ryan Adsit

In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Sell rating on Bluebird Bio (NASDAQ: BLUE), with a price target of $37. The company’s shares opened today at $90, close to its 52-week high of $100.40.


According to, Piros is a 1-star analyst with an average return of -2.6% and a 41.7% success rate. Piros covers the Healthcare sector, focusing on stocks such as Dimension Therapeutics Inc, Global Blood Therapeutics, and Bellicum Pharmaceuticals.

Bluebird Bio has an analyst consensus of Strong Buy, with a price target consensus of $91.

The company has a one year high of $100.40 and a one year low of $36.62. Currently, Bluebird Bio has an average volume of 660K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.